- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
Pathogen: SARS-CoV-2
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Blood sample
- Adults (18-64 years)
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post COVID-19 condition
- Blood sample
- Adults (18-64 years)
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Community
- SARS-CoV-2
- Acute COVID-19
- Nasopharyngeal swab
- Non pharmacological intervention
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Infectious diseases unit
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Tixagevimab/Cilgavimab
- Elderly (≥65 years)
- Fragile population
- Outpatient clinic
- Community
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Molnupiravir